About Prostate Cancer Research
Prostate Cancer Research (PCR) is a research and information provision charity that is dedicated to improving and saving the lives of people with prostate cancer. Patients are central to everything we do and drive our work. We focus on four core programmes of work:
- Academic and social research – We fund novel and innovative research projects at world-leading institutions that are working towards breakthroughs in the prevention, diagnosis and treatment of advanced prostate cancer, and better quality of life outcomes for patients. We ensure that our research is targeted to address patient need and research gaps to maximise our impact and reach better treatments for patients sooner.
- Translational research – We set up Proven Connect, the translational research arm of PCR, to focus on ensuring more promising treatments get from lab to patient through bridging the gap between industry, investors, health providers and patients.
- Patient information and empowerment – We acknowledge that research alone is not enough to achieve our vision. We involve, educate, and empower people affected by prostate cancer to enable them to play a more active role in driving forward changes in research, treatment and care.
- Influencing – We seek to ensure greater equity of treatment and parity of care, and are working towards a world where no man is left behind, where prostate cancer is caught early and can be cured.
Over the last few years, we have successfully diversified our income streams, improving our capability of raising restricted funds for specific projects by focusing on Trusts & Foundations, Statutory, Corporates, and Major Donors. At the same time, we ensure that we have flexible and sustainable unrestricted funding through our Events & Community, Legacies, and Individual Giving. The target now, as part of PCR’s Fundraising Strategy for 2021-26, is to grow our income year on year to £9.8 million by 2026. Since 2020, PCR has significantly increased its work with corporate partners and associated income. A core driver for this has been our collaboration with pharmaceutical, biotechnology and healthcare related companies.